2016 | Fourth Midkine Symposium Delegate


Back to Program

Dr Vicki Campbell

Nambour General Hospotal 

Sunshine Coast, Australia

Vicki Campbell completed her medical degree through the University of Adelaide in 1996. She completed both Nephrology and Intensive Care training programs in 2006 and 2009 respectively, and for the last 10 years has practiced clinically in both fields on the Sunshine Coast in Queensland, Australia. Although heavily bedside focussed, in recent years she has become increasingly engaged in research, and in 2012 was honoured with an invitation to become a reviewer and editorialist for New England Journal of Medicine.

Her fields of interest have developed diversely, being driven by a focus on patient-outcome centred investigation, and a "prevention is better than cure" approach. As a result, she is involved in a number of hospital-based patient safety and harm prevention initiatives. Connecting with Cellmid, and Midkine, has meant the potential to identify, delay or prevent end stage renal failure and its associated risk of death or dialysis. Diving deep into molecular mechanisms has proved an exciting challenge, and exploring MK has created an exciting opportunity to move into progressive directions of research, including bench-to-bedside, and investigator-industry participation ventures.

Vicki has been working with Cellmid since 2012, exploring MK's potential in human kidney disease, a disease for which there is currently no treatment. She continues to engage key researchers and research groups, aiming to increase our understanding of MK's role as a biomarker and a therapeutic target in both acute and chronic KD


Thursday 28 April, 11:30am-12:00pm (Session 2)


Circulating and urinary midkine levels in kidney disease